替罗非班对急性心肌梗死介入术后可溶性CD40配体的影响

Effects of tirofiban on soluble CD40 ligand in acute myocardial infarction patients after percutaneous coronary intervention

目的观察急性ST段抬高型心肌梗死患者介入术前应用替罗非班治疗对可溶性CD40配体（sCD40L）和高敏C反应蛋白（hs—CRP）水平的影响。方法将入选的80例急性ST段抬高型心肌梗死患者随机分为对照组和替罗非班组，均接受常规药物和介入治疗，替罗非班组加用替罗非班泵入。比较两组术前及术后24hsCD40L和hs—CRP水平。结果两组患者一般情况和血管情况比较差异无统计学意义（P〉0．05），术前hs—CRP和sCD40L水平比较差异无统计学意义（P〉0．05），介入术后hs—CRP和sCD40L水平均明显高于术前（P〈0．05）。替罗非班组介入术后sCD40L和hs—CRP水平均明显低于对照组介入术后的水平（P〈0．05）。结论替罗非班除了具有强化抗血小板作用外，还可能通过减轻炎症反应对急性心肌梗死患者发挥有益作用。

Objective To study the effects of tirofiban on serum soluble CD40 ligand（sCD40L） and high sensitivity C reactive protein （ hs - CRP ） level in acute ST - segment elevation myocardial infarction（STEMI）. Methods 80 STEMI patients were randomly divided into control group and tirofiban group, medical and percutaneous coronary intervention （ PCI ） therapy were given to all the patients. The difference of sCD40L and hs - CRP among different groups before PCI and 24 hours after PCI were compared. Results The two groups had no differences in general data and coronary artery （ P 〉 0.05 ） , the level of sCD40L and hs - CRP had no significant differences before PCI（ P 〉0.05 ） ,the level of sCD40L and hs - CRP were significantly higher after PCI than before PCI （ P 〈 0.05 ）. In tirofiban group, the level of sCD40L and hs - CRP were significantly lower after PCI than in control group（ P 〈 0.05 ）. Conclusion In addition to anticoagulation, tirofiban also can contribute to STEMI therapy by anti - inflammatory re- action.